A detailed history of Hsbc Holdings PLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 17,676 shares of ATXS stock, worth $178,704. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,676
Previous 18,773 5.84%
Holding current value
$178,704
Previous $170,000 14.12%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.97 - $12.65 $9,840 - $13,877
-1,097 Reduced 5.84%
17,676 $194,000
Q2 2024

Aug 12, 2024

BUY
$8.83 - $13.51 $165,765 - $253,623
18,773 New
18,773 $170,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $153M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.